Supporting this, a reduction in mitochondrial ROS through SOD2-targeted therapy improved oxidative phosphorylation and preserved endothelial resilience in non-reperfused myocardial infarction, highlighting MnSOD’s therapeutic potential in protecting coronary endothelium under ischemic conditions [102]. The gene discussed is SOD2; the disease is myocardial infarction.